Skip to main content

Table 1 Baseline demographics and illness characteristics

From: Safety and efficacy of duloxetine treatment in older and younger patients with osteoarthritis knee pain: a post hoc, subgroup analysis of two randomized, placebo-controlled trials

  Older Younger Older versus younger
Variable Placebo N=94 Duloxetine N=103 Placebo N=154 Duloxetine N=136 p values
Age in years, mean (SD) 72.0 (4.0) 71.4 (4.1) 56.2 (5.7) 56.0 (5.8) <.001
Female, n (%) 72 (76.6) 61 (59.2) 116 (75.3) 98 (72.1) .19
Caucasian, n (%) 88 (93.6) 97 (94.2) 136 (88.3) 123 (90.4) .11
OA duration, years, mean (SD) 8.1 (8.1) 7.9 (8.3) 5.3 (5.5) 5.5 (6.0) <.001
OA pain, years. mean (SD) 9.4 (8.1) 10.3 (9.1) 7.1 (7.1) 7.2 (7.2) <.001
BMI (kg/m2), mean (SD) 30.0 (4.6) 30.1 (4.1) 30.9 (4.9) 29.9 (5.0) .45
Pain diary ratings, mean (SD) 6.2 (1.4) 6.0 (1.3) 6.1 (1.2) 6.1 (1.2) .56
BPI, mean (SD) 6.3 (1.5) 6.0 (1.6) 6.1 (1.4) 6.2 (1.4) .83
NSAID use, n (%)a 39 (41.5) 37 (35.9) 73 (47.4) 68 (50.0) .03
  1. aNSAID use was >14 days/month. Abbreviations: SD, standard deviation; OA, osteoarthritis; BMI, body mass index; BPI, Brief Pain Inventory, NSAID, non-steroidal anti-inflammatory drug.